To Buy or Not to Buy

At Forbes's Science Business blog Matthew Herper wonders whether Amgen should acquire Human Genome Sciences. Biotech analyst Geoffrey Porges says it should, and that the price tag could be as high as $6.5 billion. Porges points out that Benlysta, Human Genome's lupus drug, is "one of the hotter biotech products" and that Amgen has more to offer Human Genome than GlaxoSmithKline, which has the rights to co-market Benlysta, does.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.